|
|
| (67 intermediate revisions not shown.) |
| Line 1: |
Line 1: |
| - | [[Image: Nexium.jpg|300px|right|thumb| AstraZeneca’s Nexium]] | |
| | {{#tree:id=siteTree| | | {{#tree:id=siteTree| |
| | <big>The following is a list of major pharmaceutical compound targets, drugs, and information organized by disease. </big> | | <big>The following is a list of major pharmaceutical compound targets, drugs, and information organized by disease. </big> |
| Line 6: |
Line 5: |
| | | | |
| | **Alzheimer’s Disease | | **Alzheimer’s Disease |
| - | ***[[Acetylcholine]] | + | ***See: [[Alzheimer's Disease]] |
| - | ***[[Acetylcholinesterase]]
| + | |
| - | ***[[2ace|Acetylcholinesterase from Torpedo Californica]]
| + | |
| - | ***[[Flexibility of aromatic residues in acetylcholinesterase|Flexibility of Aromatic Residues in AChE]]
| + | |
| - | ***[[Amyloid Beta]]
| + | |
| - | ***[[Acetylcholine binding protein]] (AChBP)
| + | |
| - | ***[[Butyrylcholinesterase]] (BChE)
| + | |
| - | ***Drug Compounds & Substrates
| + | |
| - | ****[[AChE_bivalent_inhibitors|Bivalent Inhibitors of Acetylcholinesterase]]
| + | |
| - | ****[[AChE_bivalent_inhibitors_%28Part_II%29|Bivalent Inhibitors of Acetylcholinesterase, Part II]]
| + | |
| - | ****[[AChE_inhibitors_and_substrates|Inhibitors and Substrates of Acetylcholinesterase]]
| + | |
| - | ****[[ AChE_inhibitors_and_substrates_%28Part_II%29|Inhibitors and Substrates of Acetylcholinesterase, Part II]]
| + | |
| - | ****[[ AChE_inhibitors_and_substrates_%28Part_III%29|Inhibitors and Substrates of Acetylcholinesterase, Part III]]
| + | |
| - | ****Specific Examples:
| + | |
| - | *****[[1eve|Aricept Complexed with Acetylcholinesterase]]
| + | |
| - | *****[[2dfp|DFP (Aged) Complexed with Acetylcholinesterase]]
| + | |
| - | *****[[1ax9|Edrophonium Complexed with Acetylcholinesterase]] or [[2ack|Here]]
| + | |
| - | *****[[2j3q|Fluorophore Thioflavin T Complexed with Acetylcholinesterase]]
| + | |
| - | *****[[1dx6|Galanthamine Complexed with Acetylcholinesterase]]
| + | |
| - | *****[[1vot|Huperzine A Complexed with Acetylcholinesterase]]
| + | |
| - | *****[[1w6r|Iminium Galanthamine Derivative bound to Acetylcholinesterase]] or [[1w4l|Here]], or [[1w76|Here]].
| + | |
| - | *****[[1gqs|NAP Complexed with Acetylcholinesterase]]
| + | |
| - | *****[[1vxr|O-tthylmethylphosphonylated Acetylcholinesterase]]
| + | |
| - | *****[[2wfz|Soman Complexed with Acetylcholinesterase]] or [[2wg0|Here]], or [[2wg1|Here]], or [[1cfj|Here]], or [[1som|Here]].
| + | |
| - | *****[[1acj|Tacrine Complexed with Acetylcholinesterase]]
| + | |
| - | **** Bivalent Inhibitors
| + | |
| - | *****[[1u65|Anticancer Prodrug CPT-11 Complexed with Acetylcholinesterase]]
| + | |
| - | *****[[1eve|Aricept Complexed with Acetylcholinesterase]]
| + | |
| - | *****[[1w4l|Bis-Acting Galanthamine Derivative Complexed with Acetylcholinesterase]], or [[1w76|Here]], or [[1w6r|Here]]
| + | |
| - | *****[[2cmf|Bis-Tacrine Derivative Complexed with Acetylcholinesterase]] or [[2ckm|Here]] or [[1odc|Here]]
| + | |
| - | *****[[1acl|Bisquaternary Decamethonium Complexed with Acetylcholinesterase]]
| + | |
| - | *****[[1e3q|BW284C51 Complexed with Acetylcholinesterase]]
| + | |
| - | *****[[1zgb|Hupyridone Derivative Complexed with Acetylcholinesterase]], or [[1zgc|Here]], or [[1h22|Here]], or [[1h23|Here]]
| + | |
| - | *****[[1ut6|N-9-(1',2',3',4'-TETRAHYDROACRIDINYL)-1,8-DIAMINOOCTANE Complexed with Acetylcholinesterase]]
| + | |
| - | *****[[1jjb|PEG-SH Complexed with Acetylcholinesterase]]
| + | |
| - | ***[[Gamma-Secratase]]
| + | |
| - | ***Glutamate Receptor
| + | |
| - | ****[[Glutamate receptor (GluA2)]]
| + | |
| - | ****[[Molecular_Playground/Glutamate_Receptor|Glutamate Receptor]]
| + | |
| | | | |
| | **Anemia | | **Anemia |
| | ***[[Erythropoietin]] | | ***[[Erythropoietin]] |
| | + | |
| | + | **Antifungal |
| | + | ***[[Noxafil]] |
| | + | |
| | + | **Antimalarial |
| | + | ***[[Malarial Dihydrofolate Reductase as Drug Target]] |
| | + | |
| | + | **Anti-parasitic |
| | + | ***[[Ivermectin|Drug: Ivermectin; Target: Glutamate-gated chloride channels]] |
| | | | |
| | **Asthma and other Pulmonary Disease States | | **Asthma and other Pulmonary Disease States |
| - | ***[[Beta-2-Andrenergic Receptor]] | + | ***[[Beta-2 Adrenergic Receptor]] |
| | ***[[Leukotriene Receptor]] | | ***[[Leukotriene Receptor]] |
| | | | |
| Line 58: |
Line 28: |
| | | | |
| | **Autoimmune Diseases | | **Autoimmune Diseases |
| - | ***[[Tumor Necrosis Factor Receptor]] | + | ***[[Prolyl Endopeptidase]] |
| | + | ***[[Tumor necrosis factor receptor]] |
| | ***[[Molecular_Playground/TRAIL|Tumor-Necrosis Factor Apoptosis-Inducing Ligand]] | | ***[[Molecular_Playground/TRAIL|Tumor-Necrosis Factor Apoptosis-Inducing Ligand]] |
| | | | |
| | **Bacterial Infections | | **Bacterial Infections |
| - | ***[[Molecular_Playground/PcrA_Helicase|PcrA Helicase]] | + | *** See: [[Bacterial Infections]] |
| | + | ***[[Treatment of Tuberculosis]] |
| | | | |
| | **Blood Clots, Haemophilia, & Thrombic Events | | **Blood Clots, Haemophilia, & Thrombic Events |
| | ***[[P2Y12]] | | ***[[P2Y12]] |
| | ***Haemophilia | | ***Haemophilia |
| - | ****[[Jolanta_amblo|Factor VII]] | + | **** See: [[Hemophilia]] |
| - | ****[[Factor_IX|Factor IX]]
| + | ***[[Platelet-receptor glycoprotein Ib alpha]] |
| - | ****[[Factor_Xa|Factor Xa]]
| + | |
| | | | |
| | **Cancer | | **Cancer |
| - | ***Caspases | + | *** See: [[Cancer]] |
| - | ****[[Molecular_Playground/Caspase-6|Caspase-6]]
| + | |
| - | ****[[Molecular_Playground/Caspase-7_Dynamics|Caspase-7 Dynamics]]
| + | |
| - | ****[[Molecular_Playground/Caspase-9_Regulation|Caspase-9 Regulation]]
| + | |
| - | ***[[User:Greg_Black/Sandbox_1|Cisplatin Information]]
| + | |
| - | ***[[Michael Purol Sandbox 1|Cyclin Dependent Kinase Inhibitor]]
| + | |
| - | ***[[6-deoxyerythronolide_B_synthase_%28DEBS%29|DEBS]]
| + | |
| - | ***[[Farnesoid X Receptor]]
| + | |
| - | ***Growth Factors & Receptors
| + | |
| - | ****Epidermal Growth Factor
| + | |
| - | *****[[Epidermal Growth Factor]]
| + | |
| - | *****[[Epidermal Growth Factor Receptor]]
| + | |
| - | ****[[Hepatocyte Growth Factor Receptor]]
| + | |
| - | ****[[Human Epidermal Growth Factor Receptor 2]]
| + | |
| - | ****Insulin-Like Growth Factor
| + | |
| - | *****[[Insulin-Like Growth Factor-1]]
| + | |
| - | *****[[Insulin-Like Growth Factor-1 Receptor]]
| + | |
| - | ****Vascular Growth Factor
| + | |
| - | *****[[Vascular Endothelial Growth Factor]]
| + | |
| - | *****[[Vascular Endothelial Growth Factor Receptor]]
| + | |
| - | ***[[Molecular_Playground/FIH|Hypoxia Inducible Factor (HIF)]]
| + | |
| - | ***[[Heat Shock Protein 90]]
| + | |
| - | ***[[1ebm|Human 8-Oxoguanine Glycosylase Structure and Mechanism (HOGG1)]]
| + | |
| - | ***Kinases
| + | |
| - | ****[[Cory_Tiedeman_sandbox|Cyclin Dependent Kinase-4]]
| + | |
| - | ****[[Cell Division Cycle 7-Related Protein Kinase]]
| + | |
| - | ****[[Mammalian Target of Rapamycin]]
| + | |
| - | ****Mitogen-Activated Proteins
| + | |
| - | *****Mitogen-Activated Protein Kinase
| + | |
| - | *****Mitogen-Activated Protein Kinase Kinase
| + | |
| - | *****Mitogen-Activated Protein Kinase Kinase Kinase
| + | |
| - | ******[[c-Raf]]
| + | |
| - | ****[[Phosphatidylinositol 3-Kinase]]
| + | |
| - | ****[[SRC]]
| + | |
| - | ***[[Matt Routh sandbox|MDM2 Bound to p53]]
| + | |
| - | ***[[P-glycoprotein:_Why_Cancer_Drugs_Fail|P-Glycoprotein: Why Cancer Drugs Fail]]
| + | |
| - | ***[[p53]]
| + | |
| - | ***[[Ann_Taylor_sandbox_Proteins_in_Cancer|Proteins in Cancer]]
| + | |
| - | ***[[Chad Sorenson sandbox 1|Retinoblastoma Protein]]
| + | |
| - | ***[[Molecular_Playground/Taxol|Taxol Information]]
| + | |
| - | ***[[Molecular_Playground/TRAIL|Tumor-Necrosis Factor Apoptosis-Inducing Ligand]]
| + | |
| - | ***[[Molecular_Playground/YKL-40|YKL-40]]
| + | |
| | | | |
| | **Compromised Immune System | | **Compromised Immune System |
| | ***[[Granulocyte-macrophage colony-stimulating factor]] | | ***[[Granulocyte-macrophage colony-stimulating factor]] |
| | | | |
| - | **Delivery Systems | + | **Delivery Systems & Biotech |
| | ***[[Molecular_Playground/Targeting_Peptide|Targeted Drug Delivery]] | | ***[[Molecular_Playground/Targeting_Peptide|Targeted Drug Delivery]] |
| | + | ***[[Monoclonal Antibody]] |
| | | | |
| | **Diabetes & Hypoglycemia | | **Diabetes & Hypoglycemia |
| - | ***[[Molecular_Playground/Insulin|Insulin Information]] | + | *** See: [[Diabetes]] |
| - | ***[[User:Mary Ball/Leptin|Leptin]]
| + | |
| - | ***[[Peroxisome Proliferator-Activated Receptors]]
| + | |
| - | ***[[Molecular_Playground/YKL-40|YKL-40]]
| + | |
| | | | |
| | **Digestive Diseases | | **Digestive Diseases |
| - | ***[[Proton Pump]] | + | ***Proton Pump |
| | + | ****[[Esomeprazole and H+/K+ - ATPase Interaction]] |
| | | | |
| | **Erectile Dysfunction | | **Erectile Dysfunction |
| Line 134: |
Line 63: |
| | | | |
| | **Hypertension & Congestive Heart Failure | | **Hypertension & Congestive Heart Failure |
| - | ***[[Angiotensin-Converting Enzyme]] | + | ***See: [[Hypertension & Congestive Heart Failure]] |
| - | ***[[Calcium Channel]]
| + | |
| | | | |
| | **Inflammation & Rheumatoid Arthritis | | **Inflammation & Rheumatoid Arthritis |
| - | ***[[Cyclooxygenase]] | + | ***[[Inflammation & Rheumatoid Arthritis]] |
| - | ***[[Aspirin effects on COX aka PGHS|Asprin Effects on Cyclooxygenase]]
| + | |
| - | ***[[Molecular_Playground/YKL-40|YKL-40]]
| + | |
| | | | |
| | **Metabolic Disorders | | **Metabolic Disorders |
| - | ***[[Acid-beta-glucosidase]] | + | *** See: [[Metabolic Disorders]] |
| - | ***[[Molecular_playground/beta_2_microglobulin|ß-2 Microglobulin]]
| + | |
| - | ***[[Molecular_Playground/Human_PPCA|Protective Protein/Cathepsin A (PPCA)]]
| + | |
| - | ***[[Molecular_Playground/Human_Protective_Protein_Cathepsin_A|Protective Protein/Cathepsin A (PPCA) 2]]
| + | |
| - | ***[[Treatment_of_Gaucher_disease]]
| + | |
| - | ***[[Molecular_Playground/Velaglucerase|Velaglucerase]]
| + | |
| | | | |
| - | **Schizophrenia, Bipolar Depression, Insomnia, and Anxiety Disorders | + | **Schizophrenia, Bipolar Depression, Depression, Insomnia, and Anxiety Disorders |
| - | ***[[Dopamine Receptor]] | + | ***[[Dopamine receptor]] |
| - | ***[[Andrenergic Receptor]] | + | ***[[Adrenergic receptor]] |
| - | ***[[Histamine Receptor]] | + | ***[[Histamine H1 receptor]] |
| - | ***[[Opioid Receptor]] | + | ***[[Opioid receptor]] |
| | + | ***[[5-hydroxytryptamine receptor]] |
| | | | |
| | **Viral Infection | | **Viral Infection |
| - | ***[[Molecular_Playground/T7_RNA_Polymerase_%287_mer_int%29|T7 RNA Polymerase]] | + | ***[[Molecular_Playground/T7_RNA_Polymerase_%287_mer_int%29| T7 RNA Polymerase]] |
| - | ***HIV | + | *** HIV |
| - | ****[[HIV-1 protease|HIV-1 Protease]] | + | **** See: [[Human Immunodeficiency Virus]] |
| - | ****[[User:Tsung-Yi_Lin/Sandbox|HIV-1 Protease Analysis]]
| + | *** Influenza |
| - | ****[[HIV-1 Gag]]
| + | **** See: [[Influenza]] |
| - | ****[[HIV-1 Gag Recruitment of Tsg101 and the Viral Budding Process]] | + | *** [[Herpes Simplex Virus Thymidine Kinase]] |
| - | ****[[User:Eric Martz/Molecular Playground/HIVDrug|HIV Drug]] | + | *** [[NS5B|RNA Dependent RNA Polymerase from Hepatitis C Virus]] |
| - | ****[[Molecular_Playground/HIV_Protease_Inhibitor|HIV Protease Inhibitor]]
| + | *** Poliovirus |
| - | ****[[HIV-1_Subtype_C_Protease|HIV-1 Subtype C Protease]]
| + | ****[[Journal:PLoS ONE:1|Antiviral Activity of 3(2H)- and 6-Chloro-3(2H)-Isoflavenes against Highly Diverged, Neurovirulent Vaccine-Derived, Type2 Poliovirus Sewage Isolates]] |
| - | ****[[Reverse Transcriptase]]
| + | *** [[Interferon]] |
| - | ***Influenza
| + | |
| - | **** [[Avian Influenza Neuraminidase, Tamiflu and Relenza]]
| + | |
| - | **** [[Avian Influenza Neuraminidase, Tamiflu and Relenza]]
| + | |
| - | ****H1N1 Sequence Analyses
| + | |
| - | ****** [[User:Michael_Strong/H1N1|H1N1 Swine Flu Sequence Analysis]]
| + | |
| - | ****** [[User:Michael_Strong/H1N1/MP1/MSA|H1N1 Swine Flu Multiple Sequence Alignment]] | + | |
| - | ****** [[User:Michael Strong/H1N1/MP2/MSA|H1N1 Sequence Alignment of MP2 Protein]]
| + | |
| - | ****** [[User:Michael_Strong/H1N1/PB2|H1N1 Sequence Alignment of PB2 Protein]]
| + | |
| - | ****** [[User:Michael_Strong/H1N1/PB1|H1N1 Sequence Alignment of PB1 Protein]]
| + | |
| - | ****** [[User:Michael_Strong/H1N1/NS2/MSA|H1N1 Sequence Alignment of NS2 Protein]]
| + | |
| - | ****** [[User:Michael_Strong/H1N1/PA|H1N1 Sequence Alignment of PA Protein]]
| + | |
| - | ****** [[User:Michael_Strong/H1N1/HA|H1N1 Sequence Alignment of HA Protein]]
| + | |
| - | ****** [[User:Michael_Strong/H1N1/NP|H1N1 Sequence Alignment of NP Protein]]
| + | |
| - | ****** [[User:Michael_Strong/H1N1/NA|H1N1 Sequence Alignment of NA Protein]]
| + | |
| - | ****** [[User:Michael_Strong/H1N1/MP|H1N1 Sequence Alignment of MP Protein]]
| + | |
| - | ****** [[User:Michael_Strong/H1N1/NS|H1N1 Sequence Alignment of NS Protein]]
| + | |
| - | **** [[Influenza hemagglutinin]]
| + | |
| - | **** [[Molecular_Playground/Influenza_A_M2_transmembrane_domain|Influenza A M2 Transmembrane Domain]]
| + | |
| - | **** [[Proton Channels]] featuring a morph of the M2 proton channel of influenza.
| + | |
| - | **** [[Molecular Playground/Tamiflu|Tamiflu]]
| + | |
| - | **** [[Molecular Playground/Relenza|Relenza]]
| + | |
| | }} | | }} |
| | + | |
| | + | See [[Pharmaceutical Drugs]] for descriptions and analysis of well known drugs |